{
    "nctId": "NCT01528345",
    "briefTitle": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",
    "officialTitle": "A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 97,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS) Based on Local Investigator Assessment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women with HER2-, HR+ locally advanced or metastatic breast cancer\n* Progression on or after endocrine treatment\n* Measureable disease as per RECIST\n* ECOG 0, 1 or 2\n\nExclusion Criteria:\n\n* Evidence of CNS or leptomeningeal metastases\n* Previous treatment with fulvestrant\n* Previous chemotherapy for locally advanced or metastatic breast cancer\n* Cirrhosis or chronic active/persistent hepatitis\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}